Imunon (IMNN) Non-Current Deffered Revenue (2013 - 2021)
Imunon's (IMNN) quarterly Non-Current Deffered Revenue came in at $125000.0 in Q3 2021, down 80.0% YoY from $625000.0 in Q3 2020, and down 50.0% on a QoQ basis from $250000.0 in Q2 2021.
Imunon (IMNN) Non-Current Deffered Revenue (2013 - 2021) Analysis & Trends
Imunon (IMNN) has 9 years of Non-Current Deffered Revenue data on file, last reported at $125000.0 in Q3 2021.
- Quarterly Non-Current Deffered Revenue fell 80.0% year-over-year to $125000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $125000.0 (down 80.0% YoY) and the FY2020 annual result came in at $500000.0, down 50.0% from the prior year.
- Non-Current Deffered Revenue declined to $125000.0 in Q3 2021, from $250000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.4 million in Q1 2017 to a low of $125000.0 in Q3 2021.
- A 5-year average of $1.2 million and a median of $1.2 million in 2019 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue declined 17.39% — and 2021, when it slumped 80.0%.
- Tracing IMNN's Non-Current Deffered Revenue over 5 years: stood at $2.0 million in 2017, then retreated by 25.0% to $1.5 million in 2018, then plunged by 33.33% to $1.0 million in 2019, then slumped by 50.0% to $500000.0 in 2020, then slumped by 75.0% to $125000.0 in 2021.
- The last three Non-Current Deffered Revenue figures came in at $125000.0 (Q3 2021), $250000.0 (Q2 2021), and $375000.0 (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 125,000.00 |
| Jun 30, 2021 | 250,000.00 |
| Mar 31, 2021 | 375,000.00 |
| Dec 31, 2020 | 500,000.00 |
| Sep 30, 2020 | 625,000.00 |
| Jun 30, 2020 | 750,000.00 |
| Mar 31, 2020 | 875,000.00 |
| Dec 31, 2019 | 1.00 Mn |
| Sep 30, 2019 | 1.13 Mn |
| Jun 30, 2019 | 1.25 Mn |
| Mar 31, 2019 | 1.38 Mn |
| Dec 31, 2018 | 1.50 Mn |
| Sep 30, 2018 | 1.63 Mn |
| Jun 30, 2018 | 1.75 Mn |
| Mar 31, 2018 | 1.88 Mn |
| Dec 31, 2017 | 2.00 Mn |
| Sep 30, 2017 | 2.13 Mn |
| Jun 30, 2017 | 2.25 Mn |
| Mar 31, 2017 | 2.38 Mn |
| Dec 31, 2016 | 2.50 Mn |